Safety and efficacy of vemurafenib in end stage renal failure

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Iddawela, Mahesh ^a,b   Crook, Sarah ^a   George, Leah ^a   Lakkaraju, Amit ^c   Nanayakkara, Nihal ^a   Hunt, Roland ^a   Adam, William R ^b  

^a Goulburn Valley Area Mental Health Service   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Goulburn Valley Base Hospital   (Australia)

Author keywords

Metastatic melanoma; Renal excretion; Vemurafenib

Indexed keywords

LACTATE DEHYDROGENASE; VEMURAFENIB;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; END STAGE RENAL DISEASE; ENZYME BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; LOCAL EXCISION; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MALE; MEDICAL HISTORY; MELANOMA; MICROMETASTASIS; MIDDLE AGED; PHOTOSENSITIVITY; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SCALP; SKIN PIGMENTATION;

ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; HUMANS; INDOLES; KIDNEY FAILURE, CHRONIC; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84889068787     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-581     Document Type: Article

References (7)

1. Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEJM 2011, 364(26):2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808.
2. Davies H, Bignell GR, Cox C. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892):949-954. 10.1038/nature00766, 12068308.
3. Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother 2011, 45(11):1399-1405. 10.1345/aph.1Q363, 22028422.
4. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011, 10(11):811-812. 10.1038/nrd3579, 22037033.
5. Voiculescu M, Ionescu C, Ismail G. Frequency and prognostic significance of QT prolongation in chronic renal failure patients. Rom J Intern Med 2006, 44(4):407-417.
6. Brell JM. Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Prog Cardiovasc Dis 2010, 53(2):164-172. 10.1016/j.pcad.2010.05.005, 2956432, 20728704.
7. Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245. 10.1038/clpt.1981.154, 7249508.